董事会建议选举及委任谢东为第四届董事会独立非执行董事。谢东的委任须待股东于公司股东会上批准 后，方可作实。 大众口腔(02651)发布公告，王陶沙因其他工作安排辞任第四届董事会独立非执行董事、董事会辖下审 核委员会成员及董事会辖下提名委员会成员。王陶沙的辞任将于新委任独立非执行董事的任期开始日期 生效。 ...

董事会建议选举及委任谢东为第四届董事会独立非执行董事。谢东的委任须待股东于公司股东会上批准 后，方可作实。 智通财经APP讯，大众口腔(02651)发布公告，王陶沙因其他工作安排辞任第四届董事会独立非执行董 事、董事会辖下审核委员会成员及董事会辖下提名委员会成员。王陶沙的辞任将于新委任独立非执行董 事的任期开始日期生效。 ...

公告 (1) 建議變更獨立非執行董事 (2) 調整董事會轄下委員會成員 (3) 建議取消監事會及建議修訂公司章程及若干規則 及 (4) 暫停辦理股份過戶登記手續 建議變更獨立非執行董事 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2651） 武漢大眾口腔醫療股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）接獲本公司獨立非執行董事王陶沙女士（「王女士」）的辭 任函。王女士因其他工作安排辭任第四屆董事會獨立非執行董事、董事會轄下審 核委員會（「審核委員會」）成員及董事會轄下提名委員會（「提名委員會」）成員。 王女士的辭任將於新委任獨立非執行董事的任期開始日期生效。 王女士已確認，其與董事會並無意見分歧，亦無其他有關其辭任的事宜須提請本 公司股東（「 ...

Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 We encourage you to access Corporate Communications of the Company in electronic form on the Company's website. If you wish to receive printed copies of all future Corporate Communications, please complete and return the Request Form on the reverse side of this letter to the Company's share registrar in Hong Kong (the "Share Registrar"), Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or send an email to 26 ...

登記股東之名稱及地址 Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 （ A joint stock company with limited liability incorporated in the People's Republic of China ） ( 於中華人民共和國註冊成立的股份有限公司 ) （Stock Code 股份代號：2651） 2025 年 9 月 19 日 尊敬的股東 發佈公司通訊之安排 簡介 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 2.07A 條 1 以及武漢大眾口腔醫 療股份有限公司（「本公司」）的公司章程細則，本公司將以電子通訊方式向其股東 3 發佈本公司日後的公司通 訊（「公司通訊」2），並僅應股東要求向其寄發印刷本形式的公司通訊。 安排 1. 可供採取行動的公司通訊 4 本公司將以電子通訊方式（通過電子郵件）向股東個別地發送可供採取行動的公司通訊。如果本公司沒有獲 取股東的電子郵箱地址或其提供的電子郵箱地址無效 5，本公司將以印刷本形式向其發送可供採取行動的公 司通訊，連同一份索取 ...

武漢大眾口腔醫療股份有限公司 Wuhan Dazhong Dental Medical Co., Ltd. (A joint stock company with limited liability incorporated in the People's Republic of China)（於中華人民共和國註冊成立的股份有限公司） Stock Code 股份代號 : 2651 中期報告 2025INTERIM REPORT INTERIM REPORT 2025 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務及業務摘要 | 4 | | 管理層討論與分析 | 5 | | 企業管治與其他信息 | 15 | | 中期簡明綜合損益及全面收益表 | 21 | | 中期簡明綜合財務狀況表 | 22 | | 中期簡明綜合權益變動表 | 24 | | 中期簡明綜合現金流量表 | 26 | | 中期簡明綜合財務資料附註 | 28 | | 釋義 | 38 | 公司資料 董事會 執行董事 姚雪先生 （主席） 沈洪敏女士 郭家平先生 劉紅嬋女士 獨立非執行董事 疏義傑先生 黃素珍女士 王陶沙女士 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | | 1 RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | | 1 RMB | | 17,026,140 | | 2. 股份分類 | 普通股 ...

Core Insights - Despite challenges in the industry due to cost pressures, market competition, and consumer downgrade, Wuhan Dazhong Dental Medical Co., Ltd. reported surprising results in its 2025 semi-annual report, achieving a revenue of 186 million yuan in the first half of 2025 [1] - The company has successfully reduced marginal customer acquisition costs and increased customer lifetime value through a community-focused model, resulting in a 10.9% year-on-year decrease in sales costs to 116 million yuan, a 1.2 percentage point increase in gross margin to 37.8%, and a net profit margin growth to 15.4% [1] - The adjusted net profit, excluding IPO intermediary fees and share-based payment expenses, reached 34.438 million yuan [1] Company Strategy - As a leading player in the Central China region, Dazhong Dental achieved over 40% of new customers from 355,000 patient visits in the first half of the year, reflecting the effectiveness of its "high-frequency, low-price" strategy [1] - The company has built a dental care ecosystem centered around communities, addressing full lifecycle needs and transforming infrequent services into repeat purchase scenarios [1] - The strategic move to list on the Hong Kong stock market in July 2025 injects new momentum into the company's expansion [1] Market Position - Dazhong Dental holds a 2.4% market share in a Central China market projected to reach 25.3 billion yuan by 2029, with a CAGR of 7.8% [1] - The capitalized path enables the company to rapidly replicate its standardized operational system and community service model in other densely populated areas [1] - The "regional deep cultivation + capital empowerment" model creates a competitive advantage during the industry's increasing concentration phase [1] Industry Insights - During the industry's deep adjustment cycle, Dazhong Dental breaks through with multi-dimensional innovation, demonstrating that the dental medical sector still contains structural opportunities [2] - The company relies on a comprehensive cost optimization system, an inclusive service penetration network, and a replicable profit model, reshaping the industry's value curve [2] - This new competitive edge, centered on operational efficiency, service accessibility, and sustainable profitability, becomes a core criterion for capital markets in selecting quality targets [2]

Core Insights - The company reported a revenue decrease of 9.2% year-on-year to RMB 186 million for the six months ending June 30, 2025 [1] - Net profit also saw a decline of 2.2% year-on-year, amounting to RMB 28.6 million [1] - Despite challenging market conditions, the company focused on operational resilience and efficiency through strategic measures, particularly effective cost control [1] Financial Performance - Revenue for the six months ending June 30, 2025, was RMB 186 million, down from the previous year [1] - Net profit for the same period was RMB 28.6 million, reflecting a slight decrease [1] Market Expansion - The company opened 8 new dental clinics during the six months ending June 30, 2025 [1] - The total number of dental chairs increased by 3.6%, from 692 chairs as of June 30, 2024, to 717 chairs as of June 30, 2025 [1] Customer Engagement - The total number of patient visits reached 355,181 during the six months ending June 30, 2025 [1] - New customer visits accounted for 151,998 during the same period [1]

Group 1 - The company reported a revenue of 186 million, representing a year-on-year decrease of 9.2% [1] - Profit attributable to the parent company was 15.88 million, down 22.24% year-on-year [1] - Earnings per share stood at 0.41 [1] Group 2 - The company emphasized operational resilience and efficiency through strategic measures, particularly effective cost control under centralized management to mitigate negative impacts on profitability [1]